303 related articles for article (PubMed ID: 34811916)
21. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
Keiser MF; Patel AB; Altan M
Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
[TBL] [Abstract][Full Text] [Related]
22. Epidermal Growth Factor Receptor Inhibitor-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
Lewis W; Forrestel A; Baumrin E
Cutis; 2023 Jan; 111(1):18-21. PubMed ID: 36947773
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous Adverse Reactions of Anticancer Agents.
Kaul S; Kaffenberger BH; Choi JN; Kwatra SG
Dermatol Clin; 2019 Oct; 37(4):555-568. PubMed ID: 31466595
[TBL] [Abstract][Full Text] [Related]
24. The life-threatening eruptions of immune checkpoint inhibitor therapy.
Coleman EL; Olamiju B; Leventhal JS
Clin Dermatol; 2020; 38(1):94-104. PubMed ID: 32197753
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
26. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
Agirgol S; Çaytemel C; Pilanci KN
Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
[TBL] [Abstract][Full Text] [Related]
27. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
Amitay-Laish I; David M; Stemmer SM
Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
[TBL] [Abstract][Full Text] [Related]
28. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
[TBL] [Abstract][Full Text] [Related]
29. Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.
Mital R; Otto TS; Savu A; Baumrin E; Cardones AR; Carlesimo M; Caro G; Freites-Martinez A; Hirner JP; Markova A; McLellan BN; Rossi A; Sauder MB; Seminario-Vidal L; Sibaud V; Owen DH; Dulmage BO; Chen ST; Kaffenberger BH
Int J Dermatol; 2023 Aug; 62(8):1020-1025. PubMed ID: 37203799
[TBL] [Abstract][Full Text] [Related]
30. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
31. Eczematous Drug Eruptions.
Blum AE; Burgin S
Am J Clin Dermatol; 2021 May; 22(3):349-366. PubMed ID: 33587283
[TBL] [Abstract][Full Text] [Related]
32. Debilitating erosive lichenoid interface dermatitis from checkpoint inhibitor therapy.
Davis MJ; Wilken R; Fung MA; Tartar DM
Dermatol Online J; 2018 Apr; 24(4):. PubMed ID: 29906009
[TBL] [Abstract][Full Text] [Related]
33. Systemic Treatment of Cutaneous Adverse Events After Immune Checkpoint Inhibitor Therapy: A Review.
Brown AM; Masterson W; Lo J; Patel AB
Dermatitis; 2023; 34(3):201-208. PubMed ID: 34405836
[TBL] [Abstract][Full Text] [Related]
34. Management of Dermatologic Complications of Lung Cancer Therapies.
Pugliese SB; Neal JW; Kwong BY
Curr Treat Options Oncol; 2015 Oct; 16(10):50. PubMed ID: 26338208
[TBL] [Abstract][Full Text] [Related]
35. BRAF Inhibitors for the Treatment of Papulopustular Eruptions from MAPK Pathway Inhibitors.
Wang CJ; Brownell I
Am J Clin Dermatol; 2020 Dec; 21(6):759-764. PubMed ID: 32720072
[TBL] [Abstract][Full Text] [Related]
36. [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin].
Ehmann LM; Heinemann V; Wollenberg A
Internist (Berl); 2011 Nov; 52(11):1359-64. PubMed ID: 21796420
[TBL] [Abstract][Full Text] [Related]
37. Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review.
Ravi V; Maloney NJ; Worswick S
Dermatol Ther; 2019 Sep; 32(5):e13074. PubMed ID: 31444856
[TBL] [Abstract][Full Text] [Related]
38. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.
Pach J; Valido K; Belzer A; Leventhal JS
Am J Clin Dermatol; 2024 May; ():. PubMed ID: 38767827
[TBL] [Abstract][Full Text] [Related]
39. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician.
Gutzmer R; Becker JC; Enk A; Garbe C; Hauschild A; Leverkus M; Reimer G; Treudler R; Tsianakas A; Ulrich C; Wollenberg A; Homey B
J Dtsch Dermatol Ges; 2011 Mar; 9(3):195-203. PubMed ID: 21059173
[TBL] [Abstract][Full Text] [Related]
40. Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer.
Gisondi P; Geat D; Mattiucci A; Lombardo F; Santo A; Girolomoni G
Dermatology; 2021; 237(6):929-933. PubMed ID: 33508823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]